Skip to content
thestock.space

On 6 Nov 2026, Mankind Pharma was priced at ₹2,540.00, or 46.8× trailing earnings, against an industry P/E of 28.7×. Its ROCE of 14% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 18% and 14% a year over 3 years. Debt is 0.30× equity. It is a large-cap company with a market cap of ₹1.0 lakh crore, ranked 8th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 6.3% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹2,508.00
Day high
₹2,545.00
Day low
₹2,489.00
Prev. close
₹2,518.00
Volume
2.7 L

Health check

1 good · 2 fair · 3 to check
  • ReturnsBehind

    +6.3% over a year, better than 1 of 7 peers.

  • Price tagPricier

    P/E 46.8 vs industry 28.7.

  • GrowthStrong

    Sales +17.7%, profit +14.3% a year over 3 years.

  • ProfitabilityAverage

    ROCE 13.7% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.30× equity, interest covered 4.7×, Piotroski 7 of 9.

  • Red flags1 to check

    P/E of 46.8 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹1.0L Cr, #8 of 154 in its industry by size.

Defensive

Beta 0.43 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹15,379 Cr · profit ₹2,243 Cr
Market cap
₹1.0L Cr
Large cap
P/E
46.8
Industry 28.7
Price to book
5.97
Peers 4.99
Dividend yield
0.00%
ROE
13.6%
Peers 14.7%
ROCE
13.7%
Peers 17.9%
Debt to equity
0.30
Debt ₹5,422 Cr
EPS (TTM)
₹54.24
Face value ₹1
OPM (TTM)
26.5%
Net margin 14.6%
Sales growth
+17.3%
Latest quarter vs a year ago
Profit growth
+38.9%
Latest quarter vs a year ago
Price to sales
6.82
EV/EBITDA 26.4

Strengths and risks

Strengths

  • Quarterly profit up 38.9% on a year ago.
  • Quarterly sales up 17.3% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • P/E of 46.8 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Mankind Pharma

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer…

Headquarters
New Delhi
Employees
20,451
Sector
Healthcare
ISIN
INE634S01028
Website
mankindpharma.com

Price range

52 weeks

₹1,909.70₹2,642.00

Today

₹2,489.00₹2,545.00
Avg volume (3M)
5.5 L
1-year return
plus 6.3%
From 52-week high
minus 3.9%

Analyst consensus

19 analysts
BuyMean target ₹2,703.26 plus 6.4%

Target range, with today’s price

Low ₹2,057.00High ₹3,280.00

Next results expected around 26 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
MANKINDMankind Pharma2,540.00plus 0.87%1,04,91346.85.9713.7%13.6%26.5%17.7%14.3%0.00%plus 6.3%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
3,5703,5673,4434,0314,338
2,7242,6482,5132,9743,167
8479199301,0561,171
23.7%25.8%27.0%26.2%27.0%
83.17611748.998.5
171157142110105
219223223226236
–−107−23.2––
540509659769929
17.7%18.7%15.1%25.4%22.9%
438409554568711
10.609.8913.4113.7417.20

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+17.7%
Profit CAGR 3Y
+14.3%
EPS CAGR 3Y
+13.1%
ROE
13.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
8,74910,25912,20714,278
–+17.3%+19.0%+17.0%
6,7827,6229,07010,556
1,9682,6383,1373,721
22.5%25.7%25.7%26.1%
46.669.2111156
40.327.8421633
326398621886
23.3117310−24.7
1,6712,3982,5162,333
21.6%19.1%20.3%16.9%
1,2821,9131,9911,913
–+49.2%+4.1%minus 3.9%
32.0047.6849.1946.28

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
40.140.141.341.3
7,3959,32314,29116,259
1702078,5116,312
2,1102,3934,9165,468
9,71511,96327,76028,080
3,0763,1713,2593,714
552239351754
176122294252
1,5223,3862,4852,196
4,3905,04521,37021,164
9,71511,96327,76028,080

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,8132,1522,4133,121
−1,054−2,082−12,683−196
−7405.310,233−2,953
19.476−46.4−27.8
−832−389−531−737
9811,7631,8832,384
–––−41.3

Shareholding pattern

Source: NSE filings
72.6%
promoters
  • Promoters72.62%
  • Public27.38%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202672.62%27.38%minus 0.01
30 Jun 202672.63%27.37%minus 0.03
31 Mar 202672.66%27.34%0.00
31 Dec 202572.66%27.34%minus 0.01
30 Sep 202572.67%27.33%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you